▲
STOCKUPSIDE.IO
Analyst Price Target Intelligence
← Full Rankings
← Back to rankings
Ranked #1993 by analyst upside · 2026-09-25
STLN
The Oncology Institute, Inc.
Healthcare · Market Cap $663M · P/E 0x
ANALYST PRICE TARGET
+38.2%
implied upside to consensus target
Current Price $6.51
Consensus Target $9.0
Bull Target $11.0
Bear Target $7.0
Analysts Covering 5
ANALYST CONSENSUS - BUY
Strong Buy
1
Buy
4
Hold
0
Sell
0
52-Week Low $2.32
52-Week High $7.13
YTD Return +77.4%
FUNDAMENTALS
Market Cap $663M
P/E Ratio (TTM) N/A
Forward P/E N/A
EPS (TTM) $-0.28
PEG Ratio N/A
Dividend Yield N/A
Revenue (TTM) $587M
Profit Margin -6.2%
52-WEEK RANGE
52-Week Low $2.32
52-Week High $7.13
Current Price $6.51
Bear Target $7.0
Bull Target $11.0
● Now $6.51 ● Target $9.0
TRADING DATA
Avg Volume 1.7M
YTD Return +77.4%
Analyst Count 5
Consensus Buy
Upside to Target +38.2%
Last Updated 2026-09-25

ANALYST SUMMARY

The Oncology Institute, Inc. (STLN) is currently trading at $6.51 with a Wall Street consensus price target of $9.0, implying potential upside of 38.2% over the next 12 months. 5 analysts currently cover STLN, with a consensus rating of Buy - 100% of analysts rate the stock a Buy or Strong Buy. The most bullish analyst has a price target of $11.0, while the most cautious has a target of $7.0.

STLN operates in the Healthcare sector with a market capitalisation of $663M. The stock is up 77.4% year-to-date and is currently trading near the upper end of its 52-week range of $2.32 – $7.13.

SIMILAR STOCKS

Other Healthcare stocks with comparable size and valuation.

IRWD +45.6%
Ironwood Pharmaceuticals, Inc.
$692M · P/E 5.4x · Buy
RIGL +31.6%
Rigel Pharmaceuticals, Inc.
$895M · P/E 2.8x · Buy
INMD +13.9%
InMode Ltd.
$817M · P/E 11.7x · Hold
ABUS +10.5%
Arbutus Biopharma Corporation
$967M · P/E 6.2x · Buy
BVS +30.2%
Bioventus Inc.
$923M · P/E 17.6x · Buy

RECENT ANALYST CALLS

Upgrade/downgrade history for STLN, with each firm's 90-day track record across all stocks we track. See full firm rankings →

BTIG - Reiterated
Buy → Buy 2026-07-09 38% win rate (8 calls)
Lake Street ● Initiated
Buy 2026-07-06 27% win rate (11 calls)
Needham - Reiterated
Buy → Buy 2026-06-17 20% win rate (5 calls)
BTIG - Reiterated
Buy → Buy 2026-06-08 38% win rate (8 calls)
B. Riley Securities - Reiterated
Buy → Buy 2026-03-13 17% win rate (6 calls)
Needham reit
Buy → Buy 2026-03-13 20% win rate (5 calls)
Needham reit
Buy → Buy 2026-03-09 20% win rate (5 calls)
BTIG reit
Buy → Buy 2026-03-09 38% win rate (8 calls)
HISTORICAL SNAPSHOT

Point-in-time data from StockUpside's daily snapshots. Tracks price, analyst target, upside %, consensus, and analyst count.

Loading…
ANALYST CONVICTION SCORE
59
out of 100
Coverage depth
14/30
Consensus clarity
18/30
Vote unanimity
25/25
Rating stability
2/15

Measures analyst agreement, not fundamental quality. A high score means analysts broadly agree on this call - not that the stock will go up.

See 4,000+ stocks ranked by analyst upside

StockUpside.io tracks analyst consensus price targets across thousands of US-listed stocks, updated every day. The full ranked list is available with a Pro subscription.

View Full Rankings →